We demonstrated that exosomes derived from miR-147a-overexpression ADSCs suppressed pathological angiogenesis during AD progression by targeting VEGFA and myocyte enhancer factor 2A (MEF2A)-thymic stromal lymphopoietin (TSLP) axis, providing a potential novel therapeutic strategy for the treatment of AD. Here, MEF2A is linked to Alzheimer disease.